Results 131 to 140 of about 32,676 (224)

Prevalence of Potentially Inappropriate Apixaban Prescribing Within a Single‐Centre Tertiary Hospital

Australasian Journal on Ageing, Volume 45, Issue 2, June 2026.
ABSTRACT Objective Apixaban is widely recommended as first line therapy for atrial fibrillation (AF) and venous thromboembolism (VTE). Despite the widespread availability of dosing guidelines, anecdotal evidence suggests clinicians do not routinely follow these recommendations. Inappropriate dose reduction is associated with suboptimal patient outcomes.
Katherine J. Creeper, Grace Lenaghan, Aaron Stockwell, Matthew Schmidt, Katharine Ingram, Andrew C. Stafford   +5 more
wiley   +1 more source

CYP2C19 Polymorphism and Platelet Aggregation‐Associated Risks in Atrial Fibrillation Patients Undergoing PCI

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT CYP2C19 genetic polymorphisms impact the antiplatelet effect of clopidogrel and associate with ischemic and bleeding risk in patients undergoing percutaneous coronary intervention (PCI). This study aimed to evaluate the association of CYP2C19 and platelet reactivity (PR) with these risks, in atrial fibrillation (AF) patients undergoing PCI ...
Diona Gjermeni, Sofia Szabó, Viktoria Anfang, Hannah Vetter, Carina Juelch, Svenja Rademacher, Tian Li, Stefan Leggewie, David Hesselbarth, Daniel Duerschmied, Dietmar Trenk, Dirk Westermann, Christoph B. Olivier   +12 more
wiley   +1 more source

Impact of Intracranial Atherosclerosis and Cerebral Small Vessel Disease on Overt Vascular Events During Antithrombotic Therapy

European Journal of Neurology, Volume 33, Issue 6, June 2026.
In this prospective multicenter study, baseline MRI assessed SVD markers and ICAD severity, showing no graded association between ICAD severity and overall SVD burden, although ICAD was linked to more nonlacunar infarcts and fewer PVS. Over a median 2‐year follow‐up, severe‐to‐occluded ICAD independently increased the risk of ischemic events and ...
Kaori Miwa, Masatoshi Koga, Kanta Tanaka, Yusuke Yakushiji, Makoto Sasaki, Kohsuke Kudo, Sohei Yoshimura, Masafumi Ihara, Shigeru Fujimoto, Tadashi Terasaki, Yukako Yazawa, Yoshinari Nagakane, Hiroshi Yamagami, Kazutoshi Nishiyama, Yoshiki Yagita, Shinichi Yoshimura, Teruyuki Hirano, Kazunori Toyoda, BAT2 Investigators   +18 more
wiley   +1 more source

Prothrombin complex concentrate for oral factor Xa inhibitor reversal prior to urgent invasive procedures

Transfusion, Volume 66, Issue 6, Page 1203-1209, June 2026.
Abstract Background Oral factor Xa (FXa) inhibitors are anticoagulants with no approved reversal agent for use before urgent invasive procedures. Four‐factor prothrombin complex concentrate (4F‐PCC) is used off‐label for this despite limited evidence regarding its effectiveness and safety.
Mohammad Shamiea, Alex Osnis, Awan Kashoua, Orli Avnery, Gilad Itchaki, Shuli Isman, Tali Tohami, Osnat Jarchowsky‐Dolberg, Martin Ellis   +8 more
wiley   +1 more source

Rhythm‐Control History in AFIRE: What Can We Conclude?

Journal of Arrhythmia, Volume 42, Issue 3, June 2026.
Aytuğ Al, Şuara İrem Al, Bülent Görenek   +2 more
wiley   +1 more source

Monitoring of Rivaroxaban Therapy in Hypercoagulable Dogs

Background Measurement of rivaroxaban efficacy using the rivaroxaban‐specific anti‐Xa assay (raXa) can be used for monitoring in veterinary medicine. Detection of rivaroxaban efficacy using other hemostatic tests would make monitoring timelier and more ...
R. Darren Wood, Anthony C. G. Abrams‐Ogg, Gabrielle Monteith, Shauna L. Blois, Erin M. Phillips, Benoît Cuq   +5 more
core   +1 more source

Oral Rivaroxaban for Symptomatic Venous Thromboembolism

, 2010
BACKGROUND Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring.
Bauersachs, R., Baker, R.I.
core  

Questions and answers regarding the use of rivaroxaban in daily practice.

, 2013
Several new oral anticoagulants are now on the Swiss market and the general practitioner faces new challenges regarding the management of these new drugs. This consensus document aims to answer to the most frequently asked questions regarding rivaroxaban
Alberio, Lorenzo, Angelillo, Anne, Groupe de travail, RivaMoS Suisse   +2 more
core  

Ex Vivo Reversierung der Effekte von Rivaroxaban

, 2017
Hintergrund: Neue orale Antikoagulanzien (NOACs) können schwerwiegende Blutungen verursachen, welche die behandelnden Ärzte vor große Herausforderungen stellen.
Schenk, Bettina
core   +1 more source

Pharmacogenetic variants in pharmacokinetic and pharmacodynamic pathways and clinical factors associated with bleeding risk in Thai patients receiving rivaroxaban: a case-control study. [PDF]

Ther Adv Drug Saf
Yodsurang V, Wattanathum K, Srimatimanon T, Pitinanon K, Ranti A, Siripattarachai P, Hirunpatrawong P, Rungpradubvong V, Sakamoto S, Sujarit AS.   +9 more
europepmc   +1 more source